AU2020288030A1 - Adjuvant based on peptide nucleic acid - Google Patents

Adjuvant based on peptide nucleic acid Download PDF

Info

Publication number
AU2020288030A1
AU2020288030A1 AU2020288030A AU2020288030A AU2020288030A1 AU 2020288030 A1 AU2020288030 A1 AU 2020288030A1 AU 2020288030 A AU2020288030 A AU 2020288030A AU 2020288030 A AU2020288030 A AU 2020288030A AU 2020288030 A1 AU2020288030 A1 AU 2020288030A1
Authority
AU
Australia
Prior art keywords
adjuvant
peptide
nucleic acid
administration
mip01
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020288030A
Other languages
English (en)
Inventor
Asumi KANDA
Ryotaro MITSUMATA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denka Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Co Ltd filed Critical Denka Co Ltd
Publication of AU2020288030A1 publication Critical patent/AU2020288030A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020288030A 2019-06-06 2020-06-05 Adjuvant based on peptide nucleic acid Pending AU2020288030A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019106444 2019-06-06
JP2019-106444 2019-06-06
PCT/JP2020/022293 WO2020246584A1 (ja) 2019-06-06 2020-06-05 ペプチド核酸を基盤としたアジュバント

Publications (1)

Publication Number Publication Date
AU2020288030A1 true AU2020288030A1 (en) 2022-01-06

Family

ID=73652763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020288030A Pending AU2020288030A1 (en) 2019-06-06 2020-06-05 Adjuvant based on peptide nucleic acid

Country Status (8)

Country Link
US (1) US12016920B2 (https=)
EP (1) EP3981426A4 (https=)
JP (1) JP7602457B2 (https=)
KR (1) KR20220017919A (https=)
CN (1) CN113939313B (https=)
AU (1) AU2020288030A1 (https=)
TW (1) TW202112394A (https=)
WO (1) WO2020246584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157429A (ko) 2021-04-07 2023-11-16 덴카 주식회사 애주번트 활성 증강제 및 애주번트 조성물
JP2023128573A (ja) * 2022-03-03 2023-09-14 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
ZA200707967B (en) 2005-04-08 2008-11-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2009126933A2 (en) * 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
MX374090B (es) * 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US20160206715A1 (en) 2013-03-15 2016-07-21 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
US9902973B2 (en) * 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2018013924A1 (en) * 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds

Also Published As

Publication number Publication date
JP7602457B2 (ja) 2024-12-18
TW202112394A (zh) 2021-04-01
WO2020246584A1 (ja) 2020-12-10
KR20220017919A (ko) 2022-02-14
EP3981426A1 (en) 2022-04-13
EP3981426A4 (en) 2023-06-07
CN113939313B (zh) 2024-11-01
JPWO2020246584A1 (https=) 2020-12-10
US12016920B2 (en) 2024-06-25
CN113939313A (zh) 2022-01-14
US20230330221A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
ES2312465T3 (es) Peptidos de vih de regiones conservadas en gag p17 y sus aplicaciones, tales como vacunas.
US20250059240A1 (en) Antigenic Respiratory Syncytial Virus Polypeptides
CZ20013195A3 (cs) HIV peptidy, antigeny, vakcíny, souprava pro imunotest a způsob detekce protilátek indukovaných HIV
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
US12016920B2 (en) Adjuvant based on peptide nucleic acid
SK4012003A3 (en) Regulatory and auxiliary HIV peptides, antigens, vaccine compositions, an immunoassay kit and method of detecting antibodies induced by HIV
CN115916254A (zh) 疫苗、佐剂和产生免疫应答的方法
US20190337989A1 (en) Immunity inducer
US20240207395A1 (en) Adjuvant activity enhancer and adjuvant composition
US20060110740A1 (en) Use of sendai virus as a human parainfluenza vaccine
CN117771359A (zh) 一种包含双佐剂的rsv疫苗、制备方法及其应用
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
CN103561764A (zh) 含有瓜氨酸的佐剂组合物
RU2807992C2 (ru) Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса
US20230149534A1 (en) Haptenized coronavirus spike proteins
WO2023060220A1 (en) Methods of immunization against coronavirus
TW202306968A (zh) 用於誘導對流感病毒的特異性免疫和／或預防流感病毒相關疾病的基於流感病毒的分離重組病毒
JP2022057400A (ja) フラビウイルスに対する多重抗原ペプチドおよびこれを含む免疫原性組成物